Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010276
Filing Date
2025-05-14
Accepted
2025-05-14 16:15:42
Documents
61
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 590971
2 EX-31.1 ex31-1.htm EX-31.1 13729
3 EX-31.2 ex31-2.htm EX-31.2 19161
4 EX-32.1 ex32-1.htm EX-32.1 10501
  Complete submission text file 0001641172-25-010276.txt   3839808

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ibo-20250331.xsd EX-101.SCH 30355
6 XBRL CALCULATION FILE ibo-20250331_cal.xml EX-101.CAL 43817
7 XBRL DEFINITION FILE ibo-20250331_def.xml EX-101.DEF 125360
8 XBRL LABEL FILE ibo-20250331_lab.xml EX-101.LAB 258594
9 XBRL PRESENTATION FILE ibo-20250331_pre.xml EX-101.PRE 214795
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 473670
Mailing Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084
Business Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084 585 232 1500
IMPACT BIOMEDICAL INC. (Filer) CIK: 0001834105 (see all company filings)

EIN.: 853926944 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42212 | Film No.: 25945741
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)